Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer

(3155) Views  (646) Full article downloads

Authors: Elizabeth S Henson, James B Johnston, Marek Los, Spencer B Gibson

Published Date January 2007 Volume 2007:1(3) Pages 229 - 239

DOI: http://dx.doi.org/10.2147/BTT.S

Elizabeth S Henson¹, James B Johnston^1,2, Marek Los¹, Spencer B Gibson¹

¹Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada ²Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Abstract: The epidermal growth factor (EGF) receptors play an important role in epithelial cell function. Upon stimulation of these receptors, an extensive network of signal transduction pathways is activated, including the PI3K/AKT and Ras/Erk pathways. This activation leads to cellular proliferation and survival. In breast cancer, the EGF receptor, ErbB2 (HER2/neu), can be amplified and over-expressed and this is associated with poor prognosis and drug resistance. Trastuzumab is a monoclonal antibody against ErbB2 and has demonstrated activity in the therapy of breast cancer patients with over-expression of ErbB2, both in the metastatic and adjuvant setting. Recently, a tyrosine kinase inhibitor, lapatinib, that targets both ErbB1 and ErbB2, has also shown activity in metastatic breast cancer. In this review, we will discuss the ErbB receptors and their signaling networks in breast cancer, as well as the clinical activities of trastuzumab and lapatinib in this disease.

Keywords: trastuzumab, lapatinib, ErbB receptors, breast cancer and tyrosine kinases

Readers of this article also read: